Inflammatory biomarkers in Alzheimer's disease plasma
Uloženo v:
| Název: | Inflammatory biomarkers in Alzheimer's disease plasma |
|---|---|
| Autoři: | Morgan, Angharad R., Touchard, Samuel, Leckey, Claire, O'Hagan, Caroline, Nevado-Holgado, Alejo J., Barkhof, Frederik, Bertram, Lars, Blin, Olivier, Bos, Isabelle, Dobricic, Valerija, Engelborghs, Sebastiaan, Frisoni, Giovanni, Froelich, Lutz, Gabel, Silvey, Johannsen, Peter, Kettunen, Petronella, Koszewska, Iwona, Legido-Quigley, Cristina, Lleo, Alberto, Martinez-Lage, Pablo, Mecocci, Patrizia, Meersmans, Karen, Luis Molinuevo, Jose, Peyratout, Gwendoline, Popp, Julius, Richardson, Jill, Sala, Isabel, Scheltens, Philip, Streffer, Johannes, Soininen, Hikka, Tainta-Cuezva, Mikel, Teunissen, Charlotte, Tsolaki, Magda, Vandenberghe, Rik, Visser, Pieter Jelle, Vos, Stephanie, Wahlund, Lars-Olof, Wallin, Anders, Westwood, Sarah, Zetterberg, Henrik, Lovestone, Simon, Morgan, B. Paul, Bullmore, Edward T., Bhatti, Junaid, Chamberlain, Samuel J., Correia, Marta M., Crofts, Anna L., Dickinson, Amber, Foster, Andrew C., Kitzbichler, Manfred G., Knight, Clare, Lynall, Mary-Ellen, Maurice, Christina, O'Donnell, Ciara, Pointon, Linda J., Hyslop, Peter St George, Turner, Lorinda, Vertes, Petra, Widmer, Barry, Williams, Guy B., Leckey, ClaireA., Cavanagh, Jonathan, Deith, Catherine, Farmer, Scott, McClean, John, McColl, Alison, McPherson, Andrew, Scouller, Paul, Sutherland, Murray, Boddeke, H.WG.M. Erik, Richardson, Jill C., Khan, Shahid, Murphy, Phil, Parker, Christine A., Patel, Jai, Jones, Declan, de Boer, Peter, Kemp, John, Drevets, Wayne C., Nye, Jeffrey S., Wittenberg, Gayle, Isaac, John, Bhattacharya, Anindya, Carruthers, Nick, Kolb, Hartmuth, Pariante, Carmine M., Turkheimer, Federico, Barker, Gareth J., Byrom, Heidi, Cash, Diana, Cattaneo, Annamaria, Gee, Antony, Hastings, Caitlin, Mariani, Nicole, McLaughlin, Anna, Mondelli, Valeria, Nettis, Maria, Nikkheslat, Naghmeh, Randall, Karen, Sheridan, Hannah, Simmons, Camilla, Singh, Nisha, Van Loo, Victoria, Vicente-Rodriguez, Marta, Wood, Tobias C., Worrell, Courtney, Zajkowska, Zuzanna, Plath, Niels, Egebjerg, Jan, Eriksson, Hans, Gastambide, Francois, Adams, Karen Husted, Jeggo, Ross, Thomsen, Christian, Pederson, Jan Torleif, Campbell, Brian, Moller, Thomas, Nelson, Bob, Zorn, Stevin, O'Connor, Jason, Attenburrow, Mary Jane, Baird, Alison, Benjamin, Jithen, Clare, Stuart, Cowen, Philip, Huang, I-Shu Dante, Hurley, Samuel, Jones, Helen, Mada, Francisca, Nevado-Holgado, Alejo, Oladejo, Akintayo, Ribe, Elena, Smith, Katy, Vyas, Anviti, Hughes, Zoe, Balice-Gordon, Rita, Duerr, James, Piro, Justin R., Sporn, Jonathan, Perry, V. Hugh, Cleal, Madeleine, Fryatt, Gemma, Gomez-Nicola, Diego, Mancuso, Renzo, Reynolds, Richard, Harrison, Neil A., Cercignani, Mara, Clarke, Charlotte L., Hoskins, Elizabeth, Kohn, Charmaine, Murray, Rosemary, Wilcock, Lauren, Wlazly, Dominika |
| Přispěvatelé: | NIMA Consortium, Annex: NIMA-Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease, Bullmore, E.T., Bhatti, J., Chamberlain, S.J., Correia, M.M., Crofts, A.L., Dickinson, A., Foster, A.C., Kitzbichler, M.G., Knight, C., Lynall, M.E., Maurice, C., O'Donnell, C., Pointon, L.J., St George Hyslop, P., Turner, L., Vertes, P., Widmer, B., Williams, G.B., Morgan, B.P., Leckey, C.A., Morgan, A.R., O'Hagan, C., Touchard, S., Cavanagh, J., Deith, C., Farmer, S., McClean, J., McColl, A., McPherson, A., Scouller, P., Sutherland, M., Boddeke, HWGM, Richardson, J.C., Khan, S., Murphy, P., Parker, C.A., Patel, J., Jones, D., de Boer, P., Kemp, J., Drevets, W.C., Nye, J.S., Wittenberg, G., Isaac, J., Bhattacharya, A., Carruthers, N., Kolb, H., Pariante, C.M., Turkheimer, F., Barker, G.J., Byrom, H., Cash, D., Cattaneo, A., Gee, A., Hastings, C., Mariani, N., McLaughlin, A., Mondelli, V., Nettis, M., Nikkheslat, N., Randall, K., Sheridan, H., Simmons, C., Singh, N., Van Loo, V., Vicente-Rodriguez, M., Wood, T.C., Worrell, C., Zajkowska, Z., Plath, N., Egebjerg, J., Eriksson, H., Gastambide, F., Adams, K.H., Jeggo, R., Thomsen, C., Pederson, J.T., Campbell, B., Möller, T., Nelson, B., Zorn, S., O'Connor, J., Attenburrow, M.J., Baird, A., Benjamin, J., Clare, S., Cowen, P., Huang, I.D., Hurley, S., Jones, H., Lovestone, S., Mada, F., Nevado-Holgado, A., Oladejo, A., Ribe, E., Smith, K., Vyas, A., Hughes, Z., Balice-Gordon, R., Duerr, J., Piro, J.R., Sporn, J., Perry, V.H., Cleal, M., Fryatt, G., Gomez-Nicola, D., Mancuso, R., Reynolds, R., Harrison, N.A., Cercignani, M., Clarke, C.L., Hoskins, E., Kohn, C., Murray, R., Wilcock, L., Wlazly, D., Mount, H., Otten, Lisa, Clinical sciences, Neurology, Faculty of Arts and Philosophy, DSpace at Cambridge pro (8.1) |
| Zdroj: | Alzheimers Dement Morgan, A R, Touchard, S, Leckey, C, O'Hagan, C, Nevado-Holgado, A J, Barkhof, F, Bertram, L, Blin, O, Bos, I, Dobricic, V, Engelborghs, S, Frisoni, G, Frölich, L, Gabel, S, Johannsen, P, Kettunen, P, Kłoszewska, I, Legido-Quigley, C, Lleó, A, Martinez-Lage, P, Mecocci, P, Meersmans, K, Molinuevo, J L, Peyratout, G, Popp, J, Richardson, J, Sala, I, Scheltens, P, Streffer, J, Soininen, H, Tainta-Cuezva, M, Teunissen, C, Tsolaki, M, Vandenberghe, R, Visser, P J, Vos, S, Wahlund, L-O, Wallin, A, Westwood, S, Zetterberg, H, Lovestone, S, Morgan, B P, Bullmore, E T, Bhatti, J, Chamberlain, S J, Correia, M M, Crofts, A L, Dickinson, A, Foster, A C, Kitzbichler, M G, NIMA Consortium & Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease 2019, 'Inflammatory biomarkers in Alzheimer's disease plasma', Alzheimer's and Dementia, vol. 15, no. 6, pp. 776-787. https://doi.org/10.1016/j.jalz.2019.03.007 Alzheimer's & dementia, vol. 15, no. 6, pp. 776-787 |
| Informace o vydavateli: | Wiley, 2019. |
| Rok vydání: | 2019 |
| Témata: | MILD COGNITIVE IMPAIRMENT, Internationality, COMPLEMENT, SERUM, Cohort Studies, Plasma, 0302 clinical medicine, NIMA Consortium, RISK, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, Alzheimer's disease, Prognosis, 3. Good health, Complement Factor H, biomarker, Biomarker, Complement, Inflammation, Life Sciences & Biomedicine, Aged, Alzheimer Disease/blood, Alzheimer Disease/diagnosis, Amyloid beta-Peptides/blood, Biomarkers/blood, Cognitive Dysfunction/blood, Cognitive Dysfunction/diagnosis, Complement Factor B, Humans, FACTOR-H, Clinical Neurology, IDENTIFIES VARIANTS, Article, 03 medical and health sciences, CEREBROSPINAL-FLUID, Alzheimer Disease, Cognitive Dysfunction, GENOME-WIDE ASSOCIATION, plasma, Science & Technology, Amyloid beta-Peptides, [SCCO.NEUR] Cognitive science/Neuroscience, 3202 Clinical sciences, 1103 Clinical Sciences, Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease, inflammation, Geriatrics, 5202 Biological psychology, 3209 Neurosciences, IMMUNE-SYSTEM, Neurosciences & Neurology, 1109 Neurosciences, Biomarkers |
| Popis: | IntroductionPlasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well‐established plasma markers.MethodsA hypothesis‐led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.ResultsTen analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP‐1, eotaxin‐1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP‐1, eotaxin‐1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).DiscussionPlasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation. |
| Druh dokumentu: | Article Conference object Other literature type |
| Popis souboru: | application/pdf; text |
| Jazyk: | English |
| ISSN: | 1552-5279 1552-5260 |
| DOI: | 10.1016/j.jalz.2019.03.007 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/31047856 https://orca.cardiff.ac.uk/id/eprint/122268/1/Morgan_InfBiomarkers_AD_Plasma_2019.pdf https://researchportal.vub.be/en/publications/inflammatory-biomarkers-in-alzheimers-disease-plasma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565806 https://www.rug.nl/research/portal/publications/inflammatory-biomarkers-in-alzheimers-disease-plasma(70c00518-6936-4ffb-919b-f1ec896fdeb3).html https://www.ncbi.nlm.nih.gov/pubmed/31047856 https://www.psych.ox.ac.uk/publications/995651 https://pure.rug.nl/ws/files/84873912/1_s2.0_S1552526019300780_main.pdf https://research.vumc.nl/en/publications/52b60963-ae6a-4d4c-8d3d-2c92b9d4a260 http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_E5F2C092E3542 https://serval.unil.ch/resource/serval:BIB_E5F2C092E354.P001/REF.pdf https://serval.unil.ch/notice/serval:BIB_E5F2C092E354 https://biblio.vub.ac.be/vubir/inflammatory-biomarkers-in-alzheimers-disease-plasma(5d9a021d-1b62-40b2-9bf3-7e4d5ac762da).html https://eprints.soton.ac.uk/431827/ |
| Rights: | Wiley Online Library User Agreement CC BY unspecified |
| Přístupové číslo: | edsair.doi.dedup.....dfd0ef5932d5725f451a888f2eb5ef09 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | IntroductionPlasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well‐established plasma markers.MethodsA hypothesis‐led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.ResultsTen analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP‐1, eotaxin‐1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP‐1, eotaxin‐1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).DiscussionPlasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation. |
|---|---|
| ISSN: | 15525279 15525260 |
| DOI: | 10.1016/j.jalz.2019.03.007 |